Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Individualised therapy in advanced urothelial cancer: Prime time?

Chemotherapy, immunotherapy or combinations: What is the best option in the face of new evidence?


16 Oct 2020


Individualised therapy in advanced urothelial cancer: Prime time?


Cytotoxic Therapy;  Immunotherapy

Tumour Site

Urothelial Cancer


Alison Birtle


A. Birtle

Author affiliations

  • Royal Preston Hospital-Lancashire Teaching Hospitals NHS Foundation Trust, PR2 9HT - Preston/GB


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.